Anthim obiltoxaximab: Phase III data

A double-blind, placebo-controlled, U.S. Phase III trial in 70 healthy adult volunteers showed that repeat doses of 16 mg/kg IV obiltoxaximab

Read the full 217 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE